Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

International Multi-Site Clinical Validation of Point-of-Care Microchip Electrophoresis Test for Hemoglobin Variant Identification

Blood (2019) 134 (Supplement_1): 3373.

https://doi.org/10.1182/blood-2019-129336

Published: 2019

Journal Articles

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

Sravanti Rangaraju, MBBS, Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Larry D Cripe, MD, Katie J Sargent, RN, G. David Roodman, MD PhD, Hamid Sayar, MD MSc, Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Rajasubramaniam Shanmugam, PhD, Adriana Rogozea, Heiko Konig, MD PhD, Reuben Kapur, PhD, H. Scott Boswell, MD

Blood (2018) 132 (Supplement 1): 3949.

https://doi.org/10.1182/blood-2018-99-111181

Published: 2018

Journal Articles

Cyclic Administration of Combination of Sorafenib and Vorinostat In Poor-Risk AML: A Pharmacodynamically-Oriented Extended Phase I Trial

Hamid Sayar, MD, Larry Cripe, MD, Mary Cangany, Jill Weisenbach, RN, OCN, Katie J. Sargent, RN, Chirayu Goswami, PhD., Lang Li, PhD., Annique Wilson-Weekes, MS, Rajasubramaniam Shanmugam, PhD, H. Scott Boswell, MD

Blood (2010) 116 (21): 3272.

https://doi.org/10.1182/blood.V116.21.3272.3272

Published: 2010

Journal Articles

A Pathway-focused GSEA Platform In AML That Interrogates Interaction of Flt3ITD and tMLL with Their Epigenetic Targets (p16INK4a, DAPK1, and RUNX3), While Accurately Reporting Broad-based AML Prognosis and Targeting-agent Sensitivity.

Tareq Al Baghdadi, MD, Chirayu Goswami, PhD., Hamid Sayar, MD, Katie J. Sargent, RN, Larry Cripe, MD, Lang Li, PhD., Rajasubramaniam Shanmugam, H. Scott Boswell, MD

Blood (2010) 116 (21): 1660.

https://doi.org/10.1182/blood.V116.21.1660.1660

Published: 2010

Journal Articles

Transcriptional Repression of DAPK1 Characterizes a Resistant Phenotype of AML Enforced by Flt3 Signaling and Exclusive Nuclear Abundance of Non-Canonical NFkB2/p52: Synergistic Activity for Flt3 Inhibition along with HDAC Inhibition, or by NFkB Inhibition, for Potentiating ER Stress Apoptosis.

Rajasubramaniam Shanmugam, PhD., Annique Wilson-Weekes, MS, Hamid Sayar, MD, Attaya Suvannasankha, MD, Angelo A. Cardoso, MD., PhD, Katie J Sargent, RN, Larry D. Cripe, MD, Dhananjaya V Kalvakolanu, PhD., H. Scott Boswell, MD

Blood (2009) 114 (22): 2387.

https://doi.org/10.1182/blood.V114.22.2387.2387

Published: 2009

Journal Articles

The Sesquiterpene Lactone Parthenolide Induces Apoptosis and Overcomes the Protective Effect of the Bone Marrow Microenvironment in Human Multiple Myeloma Cells.

Attaya Suvannasankha, MD, Colin D. Crean, Rajasubramaniam Shanmugam, PhD, Rafat Abonour, MD, H. Scott Boswell, MD, Harikrishna Nakshatri, PhD

Blood (2006) 108 (11): 5058.

https://doi.org/10.1182/blood.V108.11.5058.5058

Published: 2006

NARROW

International Multi-Site Clinical Validation of Point-of-Care Microchip Electrophoresis Test for Hemoglobin Variant Identification

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

Cyclic Administration of Combination of Sorafenib and Vorinostat In Poor-Risk AML: A Pharmacodynamically-Oriented Extended Phase I Trial

A Pathway-focused GSEA Platform In AML That Interrogates Interaction of Flt3ITD and tMLL with Their Epigenetic Targets (p16INK4a, DAPK1, and RUNX3), While Accurately Reporting Broad-based AML Prognosis and Targeting-agent Sensitivity.

Transcriptional Repression of DAPK1 Characterizes a Resistant Phenotype of AML Enforced by Flt3 Signaling and Exclusive Nuclear Abundance of Non-Canonical NFkB2/p52: Synergistic Activity for Flt3 Inhibition along with HDAC Inhibition, or by NFkB Inhibition, for Potentiating ER Stress Apoptosis.

The Sesquiterpene Lactone Parthenolide Induces Apoptosis and Overcomes the Protective Effect of the Bone Marrow Microenvironment in Human Multiple Myeloma Cells.

Email alerts

ASH Publications

American Society of Hematology

International Multi-Site Clinical Validation of Point-of-Care Microchip Electrophoresis Test for Hemoglobin Variant Identification

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

Cyclic Administration of Combination of Sorafenib and Vorinostat In Poor-Risk AML: A Pharmacodynamically-Oriented Extended Phase I Trial

A Pathway-focused GSEA Platform In AML That Interrogates Interaction of Flt3ITD and tMLL with Their Epigenetic Targets (p16INK4a, DAPK1, and RUNX3), While Accurately Reporting Broad-based AML Prognosis and Targeting-agent Sensitivity.

Transcriptional Repression of DAPK1 Characterizes a Resistant Phenotype of AML Enforced by Flt3 Signaling and Exclusive Nuclear Abundance of Non-Canonical NFkB2/p52: Synergistic Activity for Flt3 Inhibition along with HDAC Inhibition, or by NFkB Inhibition, for Potentiating ER Stress Apoptosis.

The Sesquiterpene Lactone Parthenolide Induces Apoptosis and Overcomes the Protective Effect of the Bone Marrow Microenvironment in Human Multiple Myeloma Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only